INTERCEPT PHARMACEUTICALS IN's ticker is and the CUSIP is 45845PAB4. A total of 8 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q2 2022. The put-call ratio across all filers is - and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2022 | $11,232,000 | 0.0% | 18,590,000 | 0.0% | 0.14% | -12.7% |
| Q4 2021 | $11,232,000 | -8.9% | 18,590,000 | -9.7% | 0.16% | -6.2% |
| Q3 2021 | $12,327,000 | -25.6% | 20,590,000 | -17.6% | 0.18% | +36.4% |
| Q2 2021 | $16,578,000 | – | 25,000,000 | – | 0.13% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| HIGHBRIDGE CAPITAL MANAGEMENT LLC | 27,943,000 | $20,241,000 | 1.72% |
| Worth Venture Partners, LLC | 1,569,000 | $1,134,000 | 0.56% |
| Context Capital Management, LLC | 1,985,000 | $1,424,000 | 0.55% |
| ADVENT CAPITAL MANAGEMENT /DE/ | 16,703,000 | $12,060,000 | 0.28% |
| CSS LLC/IL | 6,825,000 | $4,985,000 | 0.28% |
| SILVERBACK ASSET MANAGEMENT LLC | 1,500,000 | $1,095,000 | 0.27% |
| Polar Asset Management Partners Inc. | 20,000,000 | $14,452,000 | 0.24% |
| Senvest Management, LLC | 5,000,000 | $3,621,000 | 0.23% |
| FARALLON CAPITAL MANAGEMENT LLC | 25,500,000 | $18,998,000 | 0.15% |
| LINDEN ADVISORS LP | 12,755,000 | $9,258,000 | 0.15% |